Morphine (Sulfate) Lavoisier (Morphine Sulfate)

Morphine, the active ingredient in Morphine (Sulfate) Lavoisier, is an opioid analgesic presented as a sterile injectable solution for epidural, intrathecal, and intravenous use. It provides potent analgesia for severe pain conditions in adult patients. GNH USA supplies Morphine (Sulfate) Lavoisier as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Morphine is an opioid analgesic used to manage pain across several clinical pathways. - Severe acute pain: delivers rapid, strong analgesia for trauma, injury or major surgical procedures. - Cancer‑related pain: controls persistent, moderate to severe pain associated with malignant disease. - Post‑operative pain: provides effective relief during the immediate recovery period after surgery. - Chronic non‑cancer pain: may be employed when other analgesics are insufficient, under strict medical supervision.

Morphine can cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common after administration. - Constipation: reduced bowel motility leading to hard stools. - Drowsiness or sedation: central nervous system depression. - Pruritus: itching, especially after epidural or intrathecal use. - Sweating: increased perspiration without exertion. - Dry mouth: reduced salivation causing discomfort.

Serious or Rare Side Effects: - Respiratory depression: markedly reduced breathing effort, potentially fatal. - Severe hypotension: sudden drop in blood pressure, especially with rapid IV bolus. - Addiction, dependence, or misuse: risk of tolerance and compulsive use. - Adrenal insufficiency: impaired cortisol response in chronic therapy. - Anaphylaxis or severe allergic reaction: rare but requires immediate intervention.

Morphine requires careful monitoring and adherence to safety guidelines. - Assess pain level and opioid tolerance before initiating therapy. - Avoid use in patients with significant respiratory compromise or untreated obstructive sleep apnea. - Monitor for signs of sedation, hypotension, and gastrointestinal stasis. - Adjust dose in renal or hepatic impairment to prevent accumulation. - Store below 25°C: keep in the original vial, protect from light and moisture.

Morphine interacts with several drug classes that can amplify or modify its effects.

Major Interactions (Avoid): - Central nervous system depressants (e.g., benzodiazepines, barbiturates): may cause profound sedation or respiratory depression. - Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome and severe hypotension. - Other opioids or opioid‑containing products: additive respiratory depression. - Alcohol: enhances sedative and respiratory effects. - Respiratory depressants (e.g., anesthetic gases): potentiate breathing suppression.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise morphine plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic efficacy. - Diuretics: can exacerbate orthostatic hypotension. - Anticholinergic agents: increase risk of constipation and urinary retention. - Antidepressants (e.g., SSRIs, SNRIs): may heighten serotonin syndrome risk when combined with MAOIs.